Channel 1 Industry Satellite Symposia

Novartis Oncology - What makes the difference in treating HR+, HER2– ABC? (ID 4)

Date
Thu, 06.05.2021
Time
19:00 - 20:00
Room
Channel 1
Chairs
  • S. Chia (Vancouver, BC, Canada)
Novartis Oncology - What makes the difference in treating HR+, HER2– ABC? Industry Satellite Symposia

Opening remarks (ID 349)

Lecture Time
19:00 - 19:00
Speakers
  • S. Chia (Vancouver, BC, Canada)
Session Name
Novartis Oncology - What makes the difference in treating HR+, HER2– ABC?
Room
Channel 1
Date
Thu, 06.05.2021
Time
19:00 - 20:00
Novartis Oncology - What makes the difference in treating HR+, HER2– ABC? Industry Satellite Symposia

OS data with CDK4/6i: What do the data tell us? (ID 350)

Lecture Time
19:00 - 19:10
Speakers
  • S. Chia (Vancouver, BC, Canada)
Session Name
Novartis Oncology - What makes the difference in treating HR+, HER2– ABC?
Room
Channel 1
Date
Thu, 06.05.2021
Time
19:00 - 20:00
Novartis Oncology - What makes the difference in treating HR+, HER2– ABC? Industry Satellite Symposia

Treatment decision: How tumor biology can help (ID 351)

Lecture Time
19:10 - 19:20
Speakers
  • E. Ciruelos (Madrid, Spain)
Session Name
Novartis Oncology - What makes the difference in treating HR+, HER2– ABC?
Room
Channel 1
Date
Thu, 06.05.2021
Time
19:00 - 20:00
Novartis Oncology - What makes the difference in treating HR+, HER2– ABC? Industry Satellite Symposia

Discussion (ID 352)

Lecture Time
19:20 - 19:30
Speakers
  • A. Speakers (, Switzerland)
Session Name
Novartis Oncology - What makes the difference in treating HR+, HER2– ABC?
Room
Channel 1
Date
Thu, 06.05.2021
Time
19:00 - 20:00
Novartis Oncology - What makes the difference in treating HR+, HER2– ABC? Industry Satellite Symposia

PI3Kα inhibitors: Addressing unmet needs through precision medicine in HR+, HER2- ABC - From scientific breakthrough to clinical practice (ID 353)

Lecture Time
19:30 - 19:40
Speakers
  • P. Aftimos (Brussels, Belgium)
Session Name
Novartis Oncology - What makes the difference in treating HR+, HER2– ABC?
Room
Channel 1
Date
Thu, 06.05.2021
Time
19:00 - 20:00
Novartis Oncology - What makes the difference in treating HR+, HER2– ABC? Industry Satellite Symposia

PI3Kα inhibitors: Addressing unmet needs through precision medicine in HR+, HER2- ABC - From scientific breakthrough to clinical practice (ID 354)

Lecture Time
19:40 - 19:40
Speakers
  • E. Ciruelos (Madrid, Spain)
Session Name
Novartis Oncology - What makes the difference in treating HR+, HER2– ABC?
Room
Channel 1
Date
Thu, 06.05.2021
Time
19:00 - 20:00
Novartis Oncology - What makes the difference in treating HR+, HER2– ABC? Industry Satellite Symposia

Discussion (ID 355)

Lecture Time
19:40 - 19:50
Speakers
  • A. Speakers (, Switzerland)
Session Name
Novartis Oncology - What makes the difference in treating HR+, HER2– ABC?
Room
Channel 1
Date
Thu, 06.05.2021
Time
19:00 - 20:00
Novartis Oncology - What makes the difference in treating HR+, HER2– ABC? Industry Satellite Symposia

Live Q&A session (ID 356)

Lecture Time
19:50 - 20:00
Speakers
  • A. Speakers (, Switzerland)
Session Name
Novartis Oncology - What makes the difference in treating HR+, HER2– ABC?
Room
Channel 1
Date
Thu, 06.05.2021
Time
19:00 - 20:00
Novartis Oncology - What makes the difference in treating HR+, HER2– ABC? Industry Satellite Symposia

Closing remarks (ID 357)

Lecture Time
20:00 - 20:00
Speakers
  • S. Chia (Vancouver, BC, Canada)
Session Name
Novartis Oncology - What makes the difference in treating HR+, HER2– ABC?
Room
Channel 1
Date
Thu, 06.05.2021
Time
19:00 - 20:00